{
    "nct_id": "NCT05568680",
    "official_title": "A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma",
    "inclusion_criteria": "* Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease\n* Adult 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Has at least 1 measurable lesion by iRECIST for ovarian cancer or cholangiocarcinoma or lesions measurable for mRECIST for mesothelioma.\n* Satisfactory Blood coagulation parameters\n* Satisfactory organ and bone marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian unless surgically and medically cured without evidence of recurrent disease for 5 years.\n* History of T or B cell malignancies or previous gene-engineered T cell therapies.\n* Sarcomatoid/biphasic mesothelioma.\n* Pulmonary exclusions\n* Have acquired hereditary, congenital immunodeficiency or have recognized immunodeficiency disease\n* Active hepatitis B, active hepatitis C, or any HIV infection at the time of screening\n* Active autoimmune disease",
    "miscellaneous_criteria": ""
}